Literature DB >> 6539649

Mechanisms for the renal secretion of cisplatin.

J A Nelson, G Santos, B H Herbert.   

Abstract

Cisplatin (cisDDP) inhibits the active uptake of tetraethylammonium and p-aminohippurate by mouse kidney slices. The shapes of the dose-response curves for inhibition of the organic cation and organic anion transport are different, and the inhibition is competitive in each case. Thus, the inhibition by cisDDP may be due to interaction of cisDDP or its aquated products with the specific transport sites rather than to nonspecific metabolic poisoning of the slices by cisDDP. In mice, cimetidine inhibits the renal secretion of tetraethylammonium but fails to inhibit the secretion of p-amminohippurate. The renal clearance of total platinum in mice treated with cisDDP did not exceed that of inulin; however, the clearance of platinum was reduced by cimetidine. These results suggest that the organic cation secretory system plays a role in the renal handling of cisDDP or its products.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6539649

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  9 in total

Review 1.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

Review 2.  Drug interactions at the renal level. Implications for drug development.

Authors:  P L Bonate; K Reith; S Weir
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

Review 3.  Contribution of tumoral and host solute carriers to clinical drug response.

Authors:  Jason A Sprowl; Torben S Mikkelsen; Hugh Giovinazzo; Alex Sparreboom
Journal:  Drug Resist Updat       Date:  2012-03-28       Impact factor: 18.500

4.  Nephrotoxicity of cisplatin, carboplatin and transplatin. A comparative in vitro study.

Authors:  J Hannemann; K Baumann
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

5.  Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase.

Authors:  Ryan M Franke; Ashley M Kosloske; Cynthia S Lancaster; Kelly K Filipski; Chaoxin Hu; Oliver Zolk; Ron H Mathijssen; Alex Sparreboom
Journal:  Clin Cancer Res       Date:  2010-07-02       Impact factor: 12.531

Review 6.  Polymorphic transporters and platinum pharmacodynamics.

Authors:  Jason A Sprowl; Rachel A Ness; Alex Sparreboom
Journal:  Drug Metab Pharmacokinet       Date:  2012-09-18       Impact factor: 3.614

7.  Interaction of Ethambutol with human organic cation transporters of the SLC22 family indicates potential for drug-drug interactions during antituberculosis therapy.

Authors:  Xiaolei Pan; Li Wang; Dirk Gründemann; Douglas H Sweet
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

8.  Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics.

Authors:  Jing Li; Seongho Kim; Xianyi Sha; Richard Wiegand; Jianmei Wu; Patricia LoRusso
Journal:  Clin Cancer Res       Date:  2014-06-19       Impact factor: 12.531

9.  Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance.

Authors:  J A Sprowl; L van Doorn; S Hu; L van Gerven; P de Bruijn; L Li; A A Gibson; R H Mathijssen; A Sparreboom
Journal:  Clin Pharmacol Ther       Date:  2013-07-17       Impact factor: 6.875

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.